Fosun Pharma (02196):Fosun Pharma grants New York-listed company Lilly the exclusive right to develop and commercialize BCL-2 selective small molecule inhibitor FCN-338
Zhitong Finance APP News, Fosun Pharma (02196) announced that on October 29, 2020, the company’s holding subsidiary Chuang Pharmaceutical and Lilly signed the”License Agreement” (hereinafter referred to as the”License Agreement”), and Fu Chuang Pharmaceutical awarded the Lilly within the region (all countries and regions except Mainland China, Hong Kong and Macau, the same below) and within the field ( All purposes including diagnosis, prevention, improvement and treatment of any diseases or symptoms of humans or animals, the same below) The right to exclusively develop, produce and commercialize the BCL-2 selective small molecule inhibitor FCN-338. Lilly should pay up to US$440 million (including down payment, clinical development registration and sales milestone payment) according to the contract.
The announcement stated that this cooperation will help give full play to the R&D and commercialization advantages of both parties, accelerate the global R&D registration process and market expansion of the product, and is expected to provide potential new treatments for hematological tumor patients Choose to benefit more patients with hematological tumors around the world.
It is reported that FCN-338 is a selective small molecule inhibitor of BCL-2 independently developed by Fuchuang Pharmaceutical. As of the date of this announcement, FCN-338 tablets for the treatment of hematological malignancies are in preparation for phase I clinical trials in the United States and China (excluding Hong Kong, Macao and Taiwan regions, the same below).
As of the date of this announcement, drugs with the same target as the new drug have been marketed globally, and there is no drug with independent intellectual property rights that has the same target as the new drug on the market in China. According to the latest data from IQVIA MIDASTM (provided by IQVIA, IQVIA is the world’s leading provider of professional information and strategic consulting services for the medical and health industry), in 2019, the global sales of drugs with the same target as the new drug were approximately US$749 million.
Lilly was established in 1876 and listed on the New York Stock Exchange under the stock code”LLY”. Its registered place is Indiana, USA, and its chairman and chief executive officer are Mr. David A. Ricks. Lilly is one of the world’s leading R&D pharmaceutical multinational companies, focusing on the development, manufacturing and sales of innovative biochemical drugs.